Peptides have traditionally been injected for one reason: the digestive tract destroys them. Stomach acid and protease enzymes break a peptide apart before it can be absorbed. Enteric-coated capsules solve the first half of that problem by carrying the peptide through the stomach intact and releasing it in the small intestine, where the pH is higher and absorption can happen. Topical and transdermal serums avoid the digestive tract entirely. For a practice, the result is a peptide program that the large group of needle-averse patients will say yes to. Here is how the delivery formats work, how they compare, and what needle-free delivery changes about the program you build.
Why have peptides always been injected?
Because the body treats a swallowed peptide like food. A peptide is a short chain of amino acids, and the digestive system is built to break amino-acid chains into pieces. A peptide taken by mouth without protection faces three barriers in order:
- Stomach acid and pepsin. The stomach runs at a pH of roughly 1.5 to 3.5. Acid and the enzyme pepsin start cutting the chain within minutes.
- Intestinal and pancreatic proteases. Whatever survives the stomach meets a second set of enzymes in the small intestine that work at neutral pH.
- The intestinal wall. Peptides are larger and more charged than most small-molecule drugs, so even an intact peptide has a harder time crossing the gut lining into the bloodstream.
An injection skips all three. That is why subcutaneous dosing became the default for research peptides, and it is also why peptide programs historically reached only the patients willing to self-inject. Injection comes with its own cost: a large share of patients decline it outright, and many who accept it do not stay consistent. Sharps handling, injection training, and refrigerated storage add work for staff as well. The barrier was never the peptide. It was the needle.
How does an enteric coating get a peptide past the stomach?
An enteric coating is a pH-sensitive polymer layer around the capsule. It stays intact in the acidic stomach and dissolves when it reaches the higher pH of the small intestine, typically around 6 to 7.5. The capsule passes through the stomach closed and opens where the peptide has a chance to be absorbed.
Multi-phase capsules go one step further. Instead of releasing everything at once, the capsule is staged so the contents release in phases as it moves through the intestine. That spreads exposure across a longer stretch of the gut rather than dumping the full dose at a single point.
AgeREcode's formulated products use patent-pending multi-phase enteric-coated oral capsules built on this approach. The coating handles the stomach, and the phased release handles the intestine.
One honest caveat: an enteric coating solves the acid problem, not every problem. Intestinal enzymes and gut-wall permeability still matter, which is why formulation, the choice of peptides and cofactors, and the dosing protocol all matter alongside the coating. The coating is the enabling technology. The formulation is what makes it useful.
Has an oral peptide ever been proven to work?
Yes. Oral semaglutide, sold as Rybelsus, was approved by the FDA in 2019. It is the same peptide as the injectable version, formulated with an absorption enhancer so it can be taken as a daily tablet. Its approval settled the question of whether a peptide can be delivered by mouth. It can, and one of the most prescribed peptides in the world already is.
The direction of the category is toward oral dosing. GLPLUS+, AgeREcode's metabolic product, is built around orforglipron, an oral GLP-1 receptor agonist designed for oral dosing from the start, paired with carnitines for fatty-acid oxidation. Read more about where it fits in the metabolic category in GLP-1s Are Just the Beginning: The Peptide Categories Patients Are Asking About.
Oral delivery is not a workaround for patients who refuse needles. It is where the science is going.
Ready to add peptides to your practice?
Apply for wholesale access to pricing, protocols, and sample kits.
When do topical and transdermal serums make more sense?
When the target is the skin, or the tissue directly beneath it. Cosmetic peptides like GHK-Cu and SNAP-8 act on the skin itself, so a topical serum puts the peptide where it works and skips the digestive tract entirely. Transdermal formulations extend the same idea to localized delivery through the skin.
Serums also have a practical advantage inside a program: they layer onto any protocol. A patient on an oral metabolic or recovery protocol can add a topical serum without changing anything else they are doing. AgeREcode's GHK-Cu and SNAP-8 multi-peptide serum is the product built for this, shown to improve fine lines, firmness, and hydration in a 30-day evaluation.
How do the three delivery formats compare for a practice?
| Injectable | Enteric-coated oral capsule | Topical or transdermal serum | |
|---|---|---|---|
| Who accepts it | Patients comfortable with self-injection | Nearly all patients | Nearly all patients |
| Compliance | Lowest. Daily or weekly injections are the most-skipped step in any protocol. | High. A capsule fits an existing daily routine. | High. Applied like skincare. |
| Staff time | Injection training, sharps handling, cold-chain storage | Minimal. Dispense and document. | Minimal. Dispense and document. |
| Storage | Refrigerated | Room temperature | Room temperature |
| Best fit | Single-peptide research protocols | Metabolic, recovery, cognitive, and longevity programs | Cosmetic and localized recovery use |
| AgeREcode products | Single-peptide research catalog | ReCover, ReVive, ReBalance, GLPLUS+, GLP-1 BOOST | GHK-Cu and SNAP-8 serum |
What does needle-free delivery change about the program?
Four things, and each one shows up in the numbers.
- The eligible patient pool gets bigger. Every practice has a group of patients who will never accept an injection. With oral capsules and serums, those patients become candidates for the program instead of a lost conversation. They are often the most grateful cohort, because they were excluded from the category entirely before.
- Reorders go up. Compliance drives reorders, and reorders are what make a peptide line recurring instead of episodic. A patient who takes a capsule with breakfast stays on protocol far more reliably than one who has to draw up a syringe. That is the mechanism behind how practices build a six-figure peptide revenue line.
- Staff workload goes down. No injection training, no sharps, no refrigerator log. The program runs on dispensing and documentation, which existing staff already do.
- The first conversation gets shorter. "Take one capsule a day for a week and we will check in" is a smaller ask than "learn to inject yourself." One-week trial capsules exist to make that first yes as small as possible, and the onboarding steps in Starting Patients on Peptides: A Clinical Framework for the First 90 Days build on that trial.
Delivery format is not a detail of the product. It decides who can be in the program at all, and it decides whether they stay.
Frequently Asked Questions
Can peptides be taken orally?
Yes, when the formulation protects them from the stomach. Enteric-coated capsules carry the peptide past stomach acid and release it in the small intestine. Oral semaglutide, an FDA-approved daily tablet, is the clearest proof that oral peptide delivery works.
What does enteric-coated mean?
The capsule has a pH-sensitive coating that stays intact in stomach acid and dissolves in the higher pH of the small intestine. The contents are released in the intestine rather than the stomach. Multi-phase enteric capsules stage that release across the intestine rather than all at once.
Are oral peptides as effective as injections?
It depends on the peptide and the formulation, which is why protocols are evaluated on patient outcomes over defined windows rather than assumed from the delivery route. Oral semaglutide showed that an oral peptide can match the clinical role of its injectable version. For the AgeREcode formulated line, the 90-day protocol review is where the practice measures results for each patient.
Which AgeREcode products are oral and which are topical?
ReCover, ReVive, ReBalance, GLPLUS+, and GLP-1 BOOST are multi-phase enteric-coated oral capsules. The GHK-Cu and SNAP-8 multi-peptide serum is topical. The single-peptide research catalog includes injectable formats for practices that run those protocols.
Do any patients still need injections?
Only when a protocol calls for a single research peptide that is available in injectable form. The five formulated products and the serum are needle-free, so the core program never requires an injection.
